

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2018 PC

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B45, B51; Cw6, Cw15; DR11, DR12; DQ7, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	10	10	10	10	21	21	21	21	16	16	15	16				
Positive	1	8	0	0	0	20	0	0	0	16	3	1				
Negative	9	2	10	10	21	1	21	21	16	0	12	15				
NT	3	3	3	3	6	6	6	6	10	10	11	10				
% Positive	10.0%	80.0%	0.0%	0.0%	0.0%	95.2%	0.0%	0.0%	0.0%	100.0%	20.0%	6.3%				
% Negative	90.0%	20.0%	100.0%	100.0%	100.0%	4.8%	100.0%	100.0%	100.0%	0.0%	80.0%	93.8%				
Consensus	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative				
HLA Antibody Specificity (Defined By CDC)	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES			NT	NT	NT	NT									Delayed delivery
119	YES			Negative	Positive	Negative	Negative									
120		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
128	YES			NT	NT	NT	NT									Did not perform due to workload.
133		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	NT	Negative	
139	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Quality of samples received in limits of acceptability (sample with aggregated cells).
143		YES						Negative	Negative	Negative	Negative					
147	YES	YES	YES	NT	NT	NT	NT	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	PBL's analysis is not realised because of the weak of cells.
154		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
157	YES			Negative	Positive	Negative	Negative									
159		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
163		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
169		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low B-cell viability.
193		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low B-cell viability.
194		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
195		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low B-cell viability.
197		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
209		YES						Negative	Positive	Negative	Negative					Low B-cell viability.
216		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
229	YES			Positive	Negative	Negative	Negative									
232		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Delayed delivery
235	YES			Negative	Positive	Negative	Negative									
238	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
239	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
245	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low B-cell viability.
252	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative	
260		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Low B-cell viability.
262																
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability.
293		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
294		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
297		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	
321		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2018 PC

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									50		
119	1	6	1	1									95		
120					1	6	1	1	1	6	1	1		99	99
128	NT	NT	NT	NT											
133					2	8	2	2	2	8	NT	2	85	85	85
139	1	6	1	1	1	4	1	1	1	6	6	1	75	75	60
143					1	1	1	1						>90	
147	NT	NT	NT	NT	1	8	1	1	1	8	6	1		100	85
154					1	4	1	1	1	8	1	1	95	95	90
157	1	6	1	1									100		
159					1	4	1	1	1	4	1	1		99	99
163					1	8	1	1	1	6	1	1		90	90
169					1	8	1	1	1	8	1	1			
189	1	1	1	1									90		
190					5%	90%	5%	5%	NT	NT	NT	NT		95	
193					1	6	1	1	NT	NT	NT	NT		90	
194					1	8	1	1	1	4	1	1		95	90
195					2	8	2	2	NT	NT	NT	NT		70	NT
197					NT	NT	NT	NT	NT	NT	NT	NT	60	5	40
209					1	6	1	1						95	
216					1	4	1	1	1	4	2	1		95	90
229	1.2	-	-	-									80		
232					NT	NT	NT	NT	NT	NT	NT	NT		0	0
235	1	8	1	1									85		
238	1	8	1	1	1	8	1	1	1	8	1	1	80	90	60
239	1	8	1	1	1	8	1	1	1	8	1	1	96	96	96
245	1	8	1	1	1	8	1	1	NT	NT	NT	NT	100	100	0
252	1	4-6	1	1					1	4-6	1	1	80		70
260					-	-	-	-	-	-	-	-		90	70
262													100		
292					NT	NT	NT	NT	NT	NT	NT	NT		30	25
293															
294					0	8	0	0	0	6	2	0		90	90
297					1	6	1	1	1	6	6	1		80	80
321															
351					NT	NT	NT	NT	NT	NT	NT	NT			

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2018 PC

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B45, B51; Cw6, Cw15; DR11, DR12; DQ7, DQ-

				Summary of Results													
				PBL				T-Cells				B-Cells					
Total tested	10	10	10	10	20	20	20	20	15	15	14	15					
Positive	0	7	0	0	0	17	0	0	0	15	3	1					
Negative	10	3	10	10	20	3	20	20	15	0	11	14					
NT	2	2	2	2	5	5	5	5	9	9	10	9					
% Positive	0.0%	70.0%	0.0%	0.0%	0.0%	85.0%	0.0%	0.0%	0.0%	100.0%	21.4%	6.7%					
% Negative	100.0%	30.0%	100.0%	100.0%	100.0%	15.0%	100.0%	100.0%	100.0%	0.0%	78.6%	93.3%					
Consensus	Negative	Not Assessed	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative					
HLA Antibody Specificity (Defined By CDC)	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3					
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments	
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4		
112	YES			NT	NT	NT	NT										
119	YES			Negative	Positive	Negative	Negative										
120		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
133		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	NT	Negative	Negative	
139	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative		
143		YES						Negative	Negative	Negative	Negative						
147	YES	YES	YES	NT	NT	NT	NT	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative		
157	YES			Negative	Positive	Negative	Negative										
159		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
163		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
189	YES			Negative	Negative	Negative	Negative										
190		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT		
193		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT		
194		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
195		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT		
197		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT		
209		YES						Negative	Negative	Negative	Negative						
216		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
229	YES			Negative	Negative	Negative	Negative										
235	YES			Negative	Positive	Negative	Negative										
238	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
245	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	NT	NT	NT	NT		
252	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative		
260		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive		
262	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT		
293		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT		No results returned
294		YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
297		YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative		
321		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT		No results returned
351		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT		

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2018 PC

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									50		
119	1	4	1	1									95		
120					1	6	1	1	1	6	1	1		99	99
133					2	8	2	2	2	8	NT	2	85	85	85
139	1	6	1	1	1	4	1	1	1	6	6	1	75	75	60
143					1	1	1	1						>90	
147	NT	NT	NT	NT	1	8	1	1	1	8	6	1		100	85
157	1	8	1	1									100		
159					1	4	1	1	1	4	1	1		99	99
163					1	8	1	1	1	8	1	1		90	90
169	1	8	1	1	1	8	1	1	1	8	1	1			
189	1	1	1	1									90		
190					5%	90%	5%	5%	NT	NT	NT	NT		95	
193					1	8	1	1	NT	NT	NT	NT		90	
194					1	4	1	1	1	6	1	1		95	90
195					2	8	2	2	NT	NT	NT	NT		70	NT
197					NT	NT	NT	NT	NT	NT	NT	NT	60	50	40
209					-	-	-	-						95	
216					1	4	1	1	1	4	1	1		95	90
229	-	-	-	-									80		
235	1	8	1	1									85		
238	1	8	1	1	1	8	1	1	1	8	1	1	80	90	60
245	1	8	1	1	1	8	1	1	NT	NT	NT	NT	100	100	0
252	1	4-6	1	1					1	4-6	1	1	80		70
260					-	-	-	-	-	-	-	-		90	70
262	1	1	1	1	1	1	1	1	1	8	1	1	100		
292					NT	NT	NT	NT	NT	NT	NT	NT		30	25
293															
294					0	4	0	0	0	6	2	0		90	90
297					1	4	1	1	1	6	6	1		80	80
321															
351					NT	NT	NT	NT	NT	NT	NT	NT			